Crescendo Bioscience, developer of tests that take a closer look at autoimmune and inflammatory diseases affecting joints, has raised $5 million more in a second round of venture funding, bringing its total to $20 million, according to Dow Jones VentureWire. Based in South San Francisco, the company is backed by Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.

It will use its new money to prep for the launch of its first product. The company has not revealed much about the launch, but it has been working primarily on tests for arthritis.